UTMD vs VTRS
UTMD: Utah Medical Products develops and manufactures specialized, cost-effective medical devices designed to improve patient safety and outcomes in labor, delivery, and neonatal intensive care. VTRS: A global pharmaceutical giant supplying over 1 billion patients annually with generics, branded medicines, and an expanding innovative pipeline across more than 165 countries.
Side-by-side fundamentals
| Metric | UTMD | VTRS | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $71.21 | $17.64 | |
| Market cap as of 2026-08-06 | $227M | $20.5B | |
| P/E as of 2026-08-06 | 21.22 | n/a | |
| PEG as of 2026-08-06 | n/a | 1.68 | |
| Net margin as of 2026-08-06 | +28.9% | -2.0% | UTMD higher |
| Gross margin as of 2026-08-06 | +57.9% | +39.8% | UTMD higher |
| Operating margin as of 2026-08-06 | +28.8% | +0.3% | UTMD higher |
| ROE as of 2026-08-06 | +9.1% | -2.0% | UTMD higher |
| ROA as of 2026-08-06 | +8.9% | -0.8% | UTMD higher |
| Debt / equity as of 2026-08-06 | 0.00 | 0.98 | UTMD lower |
| Revenue growth (YoY) as of 2026-08-06 | -4.4% | +1.6% | VTRS higher |
| Revenue CAGR (3y) SEC XBRL | -9.7% | -4.2% | VTRS higher |
| Dividend yield as of 2026-08-06 | +1.7% | +2.7% | VTRS higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-06 | 0.40 | 0.89 | |
| 1-year return as of 2026-08-05 close | +25.3% | +87.5% | VTRS higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.